Study of Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Carcinoma
Status:
Terminated
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the antitumor activity of sunitinib in patients with
advanced/inoperable fibrolamellar hepatocellular carcinoma.
Rationale: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth and by blocking blood flow to the tumor